NCT04719000View on ClinicalTrials.gov

PErsonalized Addition of Recombinant LH in Ovarian Stimulation

PHASE4RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 4, 2021

Primary Completion Date

August 31, 2025

Study Completion Date

November 30, 2025

Conditions
Infertility
Interventions
DRUG

rhFSH+rhLH

300 IU of rhFSH and 150 IU of rhLH (Pergoveris®) GnRH antagonist: cetrorelix 0.25 mg (Cetrotide® - Merck) GnRH antagonist: cetrorelix 0.25 mg (Cetrotide® - Merck) Recombinant human chorionic gonadotropin (rhCG) 6500 IU (Ovitrelle® - Merck) micronized progesterone 90 mg (Crinone 8% ® - Merck)

DRUG

rhFSH

300 IU rhFSH (Gonal-F®- Merck) GnRH antagonist: cetrorelix 0.25 mg (Cetrotide® - Merck) GnRH antagonist: cetrorelix 0.25 mg (Cetrotide® - Merck) rhCG 6500 IU (Ovitrelle® - Merck) micronized progesterone 90 mg (Crinone 8% ® - Merck)

Trial Locations (1)

08028

RECRUITING

Hospital Universitario Quiron Dexeus, Barcelona

All Listed Sponsors
collaborator

Merck, S.L., Spain

INDUSTRY

lead

Fundación Santiago Dexeus Font

OTHER